<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117141</url>
  </required_header>
  <id_info>
    <org_study_id>ELN-0302002</org_study_id>
    <nct_id>NCT02117141</nct_id>
  </id_info>
  <brief_title>To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules</brief_title>
  <official_title>A Pilot Study in Healthy Volunteers to Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release (HC-ER) Capsules, in Both Fed and Fasted States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Assess the rate and extent of absorption of hydrocodone from a 20 mg HC-ER capsule in&#xD;
           both fed and fasted states&#xD;
&#xD;
        -  Evaluate the safety and tolerability of the test compound administered orally&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety parameters assessed included medical history, physical examination, vital signs,&#xD;
      12-lead ECGs, clinical laboratory testing and adverse event assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the rate and extent of absorption of hydrocodone from a 20 mg HC-ER capsule in both fed and fast states</measure>
    <time_frame>Day 1-2</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HC-ER 20 mg capsule (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of a HC-ER 20 mg capsule (fasted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC-ER 20 mg capsule (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of HC-ER 20mg capsule (fed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HC-ER 20 mg capsule (fasted)</intervention_name>
    <description>Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)</description>
    <arm_group_label>HC-ER 20 mg capsule (fasted)</arm_group_label>
    <other_name>Zohydro ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HC-ER 20 mg capsule (fed)</intervention_name>
    <description>Single oral dose HC-ER 20 mg capsule after high fat meal (fed)</description>
    <arm_group_label>HC-ER 20 mg capsule (fed)</arm_group_label>
    <other_name>Zohydro ER</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Volunteers.&#xD;
&#xD;
          -  Aged greater than 18 and less than 45 years.&#xD;
&#xD;
          -  Were medically healthy with no clinically significant abnormality on the basis of&#xD;
             medical history, physical examination and laboratory evaluations&#xD;
&#xD;
          -  Volunteer consented to participate in the study.&#xD;
&#xD;
          -  Female volunteers were included if they were surgically sterile, or using an&#xD;
             acceptable method of birth control defined as either oral, injectable, implantable, or&#xD;
             barrier methods of contraception (ie, diaphragm with spermicidal cream, intrauterine&#xD;
             device (IUD) with spermicidal cream or condom with spermicidal cream).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants were in a clinical trial within the previous 90 days or participants in a&#xD;
             narcotic analgesic study within the previous 12 months.&#xD;
&#xD;
          -  Deviation in excess of 10% from the ideal body weight for height according to the&#xD;
             Metropolitan Life Insurance Tables (1983 edition).&#xD;
&#xD;
          -  History of drug or alcohol abuse at any time in the past&#xD;
&#xD;
          -  History of hypersensitivity to the study drug or similar compounds or to&#xD;
             acetaminophen.&#xD;
&#xD;
          -  Therapeutic use (for any reason) of narcotic analgesics within the previous year.&#xD;
&#xD;
          -  Subjects who used tricyclic antidepressants or monoamine oxidase inhibitors at any&#xD;
             time in the past.&#xD;
&#xD;
          -  Subjects with a history of, or clinical signs suggestive of, chronic obstructive&#xD;
             airways disease.&#xD;
&#xD;
          -  Receipt of any prescription medication (except birth control) within 2 weeks prior to&#xD;
             entry into the study or receipt of non-prescription or over-the-counter medication&#xD;
             within one week of study commencement. (Vitamin supplements were acceptable).&#xD;
&#xD;
          -  Blood donation within the 90 days previous to study entry.&#xD;
&#xD;
          -  Female volunteers with a positive serum pregnancy test, or at risk of becoming&#xD;
             pregnant during the study.&#xD;
&#xD;
          -  Volunteers with a history of smoking (must not have smoked within the last 6 months).&#xD;
&#xD;
          -  Volunteers with any clinical/biochemical impairment of liver function, or receipt of&#xD;
             known hepatic enzyme inducing or inhibiting agents within 30 days prior to entry into&#xD;
             the study.&#xD;
&#xD;
          -  History or presence of significant hepatic, renal, endocrine, cardiac, nervous,&#xD;
             gastrointestinal, pulmonary or metabolic disorders.&#xD;
&#xD;
          -  Any condition or history that the investigator considered might increase the risk to&#xD;
             the volunteer or interfere with the evaluation of data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Johnston Stewart, MB, MRCGP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zogenix, Inc.</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>April 15, 2014</last_update_submitted>
  <last_update_submitted_qc>April 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food Effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

